Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients
NCT ID: NCT00105287
Last Updated: 2014-05-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
100 participants
INTERVENTIONAL
2005-01-31
2007-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
OraVescent Fentanyl (OVF) for the Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients
NCT00105937
Evaluating the Safety and Tolerability of OraVescent Fentanyl for Opioid Tolerant Patients With Noncancer Related Breakthrough Pain
NCT00228605
Study to Evaluate the Efficacy and Safety of OraVescent Fentanyl Citrate Treatment for the Management of Breakthrough Pain in Opioid-Tolerant Patients With Noncancer-Related Chronic Pain
NCT00343733
Study to Evaluate the Efficacy and Safety of ORAVESCENT Fentanyl Citrate for the Management of Breakthrough Pain
NCT00214955
Study to Evaluate the Efficacy and Safety of ORAVESCENT Fentanyl Citrate for Management of Breakthrough Pain
NCT00214942
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
OraVescent fentanyl (OVF)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Currently taking around the clock opioid therapy for pain
* Experience on average, 1-4 breakthrough pain episodes per day
Exclusion Criteria
* Sleep apnea or active brain metastases with increased intracranial pressure
* COPD (chronic obstructive pulmonary disease); cardiopulmonary disease; heart disease
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cephalon
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cullman Oncology and Hematology
Cullman, Alabama, United States
Advanced Clinical Research Institute
Anaheim, California, United States
Pacific Cancer Medical Center
Anaheim, California, United States
Compassionate Cancer Care Medical Group
Corona, California, United States
Compassionate Cancer Center
Fountain Valley, California, United States
Clinical Trials & Research Associates, Inc.
Montebello, California, United States
San Diego Hospice & Palliative Care
San Diego, California, United States
Pacific Clinical Research
Santa Monica, California, United States
Lovelace Scientific Resources
Miami, Florida, United States
Gulf Coast Pain Specialists
Pensacola, Florida, United States
Hematology Oncology Associates of Treasure Coast
Port Saint Lucie, Florida, United States
Center for Prospective Outcome
Marietta, Georgia, United States
Iowa Pain Management Clinic, PC
Des Moines, Iowa, United States
Donald Berdeaux
Great Falls, Montana, United States
Great Falls Clinic, LLP
Great Falls, Montana, United States
Southern Nevada Cancer Research
Las Vegas, Nevada, United States
NYU Pain Management Center
New York, New York, United States
Research Across America
New York, New York, United States
Brody School of Medicine
Greenville, North Carolina, United States
Gabrail Cancer Center
Canton, Ohio, United States
Lehigh Valley Hospital
Allentown, Pennsylvania, United States
University of Pennsylvania
Philadelphia, Pennsylvania, United States
Charleston Hematology Oncology, PA
Charleston, South Carolina, United States
University of Rochester
San Antonio, Texas, United States
Lifetree Clinical Research
Salt Lake City, Utah, United States
Cache Valley Cancer Treatment and Research Clinic, Inc.
West Point, Utah, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
C25608/3039/BP/US
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.